ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$11.88 USD
+0.51 (4.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.86 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.88 USD
+0.51 (4.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.86 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Zacks News
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of 15.79% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 138.46% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength?
by Zacks Equity Research
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
by Zacks Equity Research
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
by Zacks Equity Research
ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint's (CLPT) Prism System Favored by Latest Study
by Zacks Equity Research
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.86% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -1.11% and 0.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -75.38% and 2.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 26.09% and 1.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries
by Zacks Equity Research
ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.
Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.
How Much Upside is Left in ClearPoint Neuro, Inc. (CLPT)? Wall Street Analysts Think 48.77%
by Zacks Equity Research
The mean of analysts' price targets for ClearPoint Neuro, Inc. (CLPT) points to a 48.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ClearPoint Neuro, Inc. (CLPT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?
by Zacks Equity Research
OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -61.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 34.38% and 10.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?